Supreme Court to Hear Roundup Liability Appeal Involving Bayer AG
- Supreme Court will hear Monsanto Co. v. Durnell, now owned by Bayer AG after its 2018 acquisition of Monsanto.
- Bayer argues federal pesticide law (FIFRA) preempts state failure‑to‑warn claims over Roundup liability.
- A Supreme Court decision could limit state suits against Bayer, shifting herbicide liability toward federal regulation.
Bayer’s Roundup Appeal Moves to the Supreme Court
Supreme Court Takes Up Roundup Liability Fight
The U.S. Supreme Court on Feb. 11 announces it will hear Monsanto Co. v. Durnell on April 27, taking direct aim at a high‑profile liability battle that now sits with Bayer AG following its 2018 acquisition of Monsanto. The case stems from a Missouri jury verdict that awards plaintiff John Durnell $1.25 million after finding he developed non‑Hodgkin lymphoma from exposure to Roundup, Monsanto’s glyphosate‑based weedkiller, and that the company failed to warn him. A state appeals court affirms the liability finding and the Missouri Supreme Court declines review, leaving the national litigation to the federal high court.
Bayer and its legal team argue that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) and federal pesticide labeling law preempt state failure‑to‑warn claims, contending that allowing state juries to impose liability would undercut federal regulatory judgments. The U.S. Solicitor General D. John Sauer files a brief siding with Monsanto, warning the court that permitting the Missouri ruling to stand could allow juries to second‑guess the Environmental Protection Agency’s science‑based assessments of glyphosate. Missouri legislative efforts to shield the company from state law claims fail, keeping the question of preemption squarely before the Supreme Court.
The outcome has broad implications for Bayer and the agrochemical industry by potentially constraining the pathway for state‑court product‑liability suits and steering dispute resolution toward federal agencies and statutes. Scientific disagreement deepens stakes: the World Health Organization’s cancer agency classifies glyphosate as “probably carcinogenic to humans” in 2015, while the EPA rejects that finding and California places glyphosate on a list of cancer‑causing chemicals in 2017. Plaintiffs’ lawyers say Monsanto has “known for decades” about risks and marketed Roundup as safe, allegations Bayer denies. A favorable ruling for Monsanto could narrow state remedies and alter liability landscapes for herbicides nationwide.
Privacy warrant case heads to the court
Separately, the court schedules Chatrie v. United States for April 27 to consider whether the Fourth Amendment bars warrants that collect cellphone users’ location histories near crime scenes, a decision that is likely to shape law‑enforcement practices and digital privacy standards.
FCC adjudication powers under review
The justices also set consolidated arguments in Federal Communications Commission v. AT&T and Verizon Communications v. FCC for April 21 to decide whether provisions of the Communications Act authorizing in‑house FCC adjudications and penalties are constitutional, a ruling with potential ripple effects across regulated industries and administrative‑law practice.
Related Cashu News

CRISPR Therapeutics AG Achieves Financial Progress Amid Advancements in Gene-Editing Portfolio
CRISPR Therapeutics AG (Ticker: UNDEFINED) showcases a pivotal moment in its financial journey with the release of its results for the first quarter of 2026. Highlighting a revenue of $1.46 million, t…

MetaVia to Present Innovative Cardiometabolic Research at 2026 ADA Scientific Sessions
MetaVia is set to showcase its innovative research in cardiometabolic diseases at the upcoming American Diabetes Association (ADA) Scientific Sessions in 2026, following the acceptance of three late-b…

Ionis Pharmaceuticals Advances TRYNGOLZA for Hypertriglyceridemia and Diranersen for Alzheimer's Disease
Ionis Pharmaceuticals has made headlines in the biotechnology sector with the promising potential of its drug TRYNGOLZA, which is designed to treat severe hypertriglyceridemia. During a recent healthc…

ImmunityBio Partners with BCG Laboratory to Enhance Bladder Cancer Treatment Supply and Options
ImmunityBio has secured a critical partnership with Japan's BCG Laboratory to enhance the supply of Bacillus Calmette-Guérin (BCG) in the United States, addressing an urgent need in the treatment of b…